The Medicines Company Company Profile (NASDAQ:MDCO)

About The Medicines Company (NASDAQ:MDCO)

The Medicines Company logoThe Medicines Company is a global biopharmaceutical company. The Company is focused on advancing the treatment of acute and intensive care patients through the delivery of medicines to the hospital marketplace around the world. It markets Angiomax (bivalirudin), Ionsys (fentanyl iontophoretic transdermal system), Minocin (minocycline) for injection and Orbactiv (oritavancin). It also has a pipeline of products in development, including Carbavance, inclisiran and MDCO-700. Carbavance is used for the treatment of hospitalized patients with gram-negative bacterial infections. Inclisiran is used for the treatment of hypercholesterolemia. MDCO-700 includes sedative-hypnotic, which is used to induce and maintain sedation for procedural care and general anesthesia for surgical care. In addition to these products and products in development, it has a portfolio of generic drugs.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Generic Pharmaceuticals
  • Sub-Industry: Pharmaceuticals
  • Symbol: NASDAQ:MDCO
  • CUSIP: 58468810
  • Web:
  • Market Cap: $2.79502 billion
  • Outstanding Shares: 72,167,000
Average Prices:
  • 50 Day Moving Avg: $38.40
  • 200 Day Moving Avg: $44.54
  • 52 Week Range: $30.80 - $55.95
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -10.30
  • P/E Growth: -0.09
Sales & Book Value:
  • Annual Revenue: $141.74 million
  • Price / Sales: 19.52
  • Book Value: $7.26 per share
  • Price / Book: 5.28
  • EBIDTA: ($306,000,000.00)
  • Net Margins: -91.25%
  • Return on Equity: -19.09%
  • Return on Assets: -7.60%
  • Debt-to-Equity Ratio: 0.59%
  • Current Ratio: 1.04%
  • Quick Ratio: 0.90%
  • Average Volume: 1.21 million shs.
  • Beta: 0.86
  • Short Ratio: 13.07
Frequently Asked Questions for The Medicines Company (NASDAQ:MDCO)

What is The Medicines Company's stock symbol?

The Medicines Company trades on the NASDAQ under the ticker symbol "MDCO."

How were The Medicines Company's earnings last quarter?

The Medicines Company (NASDAQ:MDCO) released its quarterly earnings results on Wednesday, July, 27th. The company reported ($0.62) EPS for the quarter, topping analysts' consensus estimates of ($1.16) by $0.54. The firm earned $54.70 million during the quarter, compared to analysts' expectations of $41.93 million. The Medicines Company had a negative net margin of 91.25% and a negative return on equity of 19.09%. The firm's revenue for the quarter was down 26.5% compared to the same quarter last year. During the same period in the previous year, the company earned ($0.65) EPS. View The Medicines Company's Earnings History.

Where is The Medicines Company's stock going? Where will The Medicines Company's stock price be in 2017?

10 brokers have issued 12 month target prices for The Medicines Company's shares. Their forecasts range from $45.00 to $65.00. On average, they expect The Medicines Company's share price to reach $55.00 in the next twelve months. View Analyst Ratings for The Medicines Company.

What are analysts saying about The Medicines Company stock?

Here are some recent quotes from research analysts about The Medicines Company stock:

  • 1. Jefferies Group LLC analysts commented, " ACC (Mar 17-19) will be a key meeting for inclisiran, where MDCO will detail full 6-mo data for ORION-1 and AMGN will present the FOURIER data. Data from the latter should help guide PIII development for inclisiran, for which MDCO continues to seek a partner. On positive FOURIER results, we lower our risk-discount on inclisiran and our PT increases to $62 (v. $49 prev)." (3/1/2017)
  • 2. According to Zacks Investment Research, "The Medicines Co. has two potential blockbusters, Inclisiran and Carbavance, in different stages of development. Moreover, divestment of non-core assets to drive shareholder value is encouraging. We are also encouraged by the company’s acquisitions and in-licensing agreements to grow its pipeline. Moreover, the company’s shares have outperformed the Zacks classified Medical-Biomedical/Genetics industry in last one year. However the company is facing generic competition for its flagship product, Angiomax. With Angiomax sales eroding due to the presence of generics, the company’s ability to successfully develop and bring new products to market is important for future growth and any regulatory setbacks would weigh heavily on the stock. Estimates have been stable lately ahead of the company’s Q4 earnings release. The company has positive record of earnings surprises in recent quarters." (1/10/2017)

Who are some of The Medicines Company's key competitors?

Who are The Medicines Company's key executives?

The Medicines Company's management team includes the folowing people:

  • Stuart A. Kingsley, President, Chief Operating Officer
  • Clive A. Meanwell M.D. Ph.D., Chief Executive Officer, Director
  • William Bernard O'Connor, Chief Financial Officer
  • Christopher T. Cox, Executive Vice President, Chief Corporate Development Officer
  • Jeffrey Frazier, Executive Vice President, Chief Human Strategy Officer
  • Stephen M. Rodin J.D., General Counsel, Secretary
  • Fredric N. Eshelman, Independent Non-Executive Chairman of the Board
  • Paris Panayiotopoulos, Director
  • William W. Crouse, Independent Director
  • Alexander J. Denner Ph.D., Independent Director

Who owns The Medicines Company stock?

The Medicines Company's stock is owned by many different of retail and institutional investors. Top institutional investors include Creative Planning (0.21%), Louisiana State Employees Retirement System (0.04%), Aperio Group LLC (0.04%), Whittier Trust Co. (0.04%), Municipal Employees Retirement System of Michigan (0.02%) and Public Employees Retirement Association of Colorado (0.02%). Company insiders that own The Medicines Company stock include Armin M Kessler, Christopher T Cox, Clive Meanwell, Elizabeth H S Wyatt, Fredric N Eshelman, Glenn Sblendorio, Hiroaki Shigeta, Melvin K Spigelman, Robert G Savage, William Bernard O'connor and William Crouse. View Institutional Ownership Trends for The Medicines Company.

Who sold The Medicines Company stock? Who is selling The Medicines Company stock?

The Medicines Company's stock was sold by a variety of institutional investors in the last quarter, including Russell Investments Group Ltd., Strs Ohio, Capstone Asset Management Co., Nisa Investment Advisors LLC, US Bancorp DE and Bank of Montreal Can. Company insiders that have sold The Medicines Company stock in the last year include Clive Meanwell and William Bernard O'connor. View Insider Buying and Selling for The Medicines Company.

Who bought The Medicines Company stock? Who is buying The Medicines Company stock?

The Medicines Company's stock was purchased by a variety of institutional investors in the last quarter, including Creative Planning, Campbell & CO Investment Adviser LLC, Parametrica Management Ltd, State of Alaska Department of Revenue, Aperio Group LLC, Municipal Employees Retirement System of Michigan, Whittier Trust Co. and Louisiana State Employees Retirement System. Company insiders that have bought The Medicines Company stock in the last two years include Christopher T Cox and Fredric N Eshelman. View Insider Buying and Selling for The Medicines Company.

How do I buy The Medicines Company stock?

Shares of The Medicines Company can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is The Medicines Company's stock price today?

One share of The Medicines Company stock can currently be purchased for approximately $38.33.

MarketBeat Community Rating for The Medicines Company (NASDAQ MDCO)
Community Ranking:  3.3 out of 5 (  )
Outperform Votes:  298 (Vote Outperform)
Underperform Votes:  153 (Vote Underperform)
Total Votes:  451
MarketBeat's community ratings are surveys of what our community members think about The Medicines Company and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for The Medicines Company (NASDAQ:MDCO) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 2 Hold Ratings, 8 Buy Ratings
Consensus Rating:Buy (Score: 2.80)
Consensus Price Target: $55.00 (43.49% upside)

Analysts' Ratings History for The Medicines Company (NASDAQ:MDCO)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
7/26/2017Citigroup Inc.Boost Price TargetNeutral$43.00 -> $45.00LowView Rating Details
6/28/2017Jefferies Group LLCReiterated RatingBuy$62.00LowView Rating Details
5/23/2017CIBCSet Price Target$50.00MediumView Rating Details
5/22/2017Oppenheimer Holdings, Inc.Initiated CoverageMarket Perform$50.00LowView Rating Details
4/19/2017Cowen and CompanyBoost Price TargetOutperform$39.00 -> $61.00LowView Rating Details
3/20/2017HC WainwrightReiterated RatingBuy$60.00HighView Rating Details
3/18/2017J P Morgan Chase & CoReiterated RatingBuyHighView Rating Details
3/1/2017Royal Bank Of CanadaReiterated RatingBuyN/AView Rating Details
1/8/2017Chardan CapitalReiterated RatingBuy$65.00N/AView Rating Details
11/18/2016GuggenheimReiterated RatingBuyN/AView Rating Details
11/8/2016Leerink SwannReiterated RatingOutperform$53.00 -> $50.00N/AView Rating Details
7/12/2016Bank of America CorporationReiterated RatingBuyN/AView Rating Details
11/6/2015Piper Jaffray CompaniesReiterated RatingNeutral$28.00 -> $31.00N/AView Rating Details
(Data available from 7/27/2015 forward)


Earnings History for The Medicines Company (NASDAQ:MDCO)
Earnings by Quarter for The Medicines Company (NASDAQ:MDCO)
Earnings History by Quarter for The Medicines Company (NASDAQ MDCO)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
4/26/2017Q1 2017($1.13)($1.44)$37.76 million$24.20 millionViewN/AView Earnings Details
2/28/2017Q416($1.43)($1.29)$26.91 million$25.20 millionViewListenView Earnings Details
10/26/2016Q316($1.38)($0.64)$37.26 million$37.60 millionViewListenView Earnings Details
7/27/2016Q216($1.16)($0.62)$41.93 million$54.70 millionViewListenView Earnings Details
5/9/2016Q116($0.89)($1.03)$48.96 million$50.30 millionViewListenView Earnings Details
2/17/2016Q415($1.54)($0.88)$64.11 million$67.20 millionViewN/AView Earnings Details
11/3/2015Q315($0.88)($0.90)$68.58 million$72.70 millionViewListenView Earnings Details
7/29/2015Q215($0.20)($0.74)$122.58 million$90.50 millionViewListenView Earnings Details
5/5/2015Q115($0.68)($0.02)$138.78 million$126.50 millionViewListenView Earnings Details
2/18/2015Q414($0.84)$0.11$188.55 million$191.00 millionViewListenView Earnings Details
10/22/2014Q314($0.10)$0.10$188.30 million$172.40 millionViewListenView Earnings Details
7/23/2014Q214($0.07)$0.22$183.75 million$183.80 millionViewListenView Earnings Details
4/23/2014Q114($0.13)$0.22$175.60 million$177.20 millionViewListenView Earnings Details
2/19/2014Q413$0.11$0.26$182.60 million$185.00 millionViewListenView Earnings Details
10/23/2013Q313$0.24$0.47$173.86 million$173.45 millionViewListenView Earnings Details
7/24/2013Q2 2013$0.33$0.50$168.70 million$172.00 millionViewListenView Earnings Details
4/24/2013Q1 2013($0.26)$0.31$152.63 million$155.80 millionViewListenView Earnings Details
2/20/2013Q4 2012$0.28$0.38$146.09 million$159.50 millionViewListenView Earnings Details
10/24/2012$0.39$0.40ViewN/AView Earnings Details
7/25/2012$0.22$0.46ViewN/AView Earnings Details
4/25/2012$0.14$0.27ViewN/AView Earnings Details
2/22/2012$0.24$0.52ViewN/AView Earnings Details
10/26/2011$0.20$0.17ViewN/AView Earnings Details
7/27/2011$0.31$0.21ViewN/AView Earnings Details
4/27/2011$0.40$0.45ViewN/AView Earnings Details
2/16/2011$0.24$0.30ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for The Medicines Company (NASDAQ:MDCO)
2017 EPS Consensus Estimate: ($5.10)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20172($1.36)($1.06)($1.21)
Q2 20173($1.40)($1.10)($1.23)
Q3 20173($1.70)($1.17)($1.51)
Q4 20173($1.36)($0.97)($1.15)
(Data provided by Zacks Investment Research)


Dividend History for The Medicines Company (NASDAQ:MDCO)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for The Medicines Company (NASDAQ:MDCO)
Insider Ownership Percentage: 7.90%
Insider Trades by Quarter for The Medicines Company (NASDAQ:MDCO)
Institutional Ownership by Quarter for The Medicines Company (NASDAQ:MDCO)
Insider Trades by Quarter for The Medicines Company (NASDAQ:MDCO)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
2/7/2017William Bernard O'connorCFOSell25,833$46.20$1,193,484.60View SEC Filing  
12/8/2016Christopher T CoxEVPBuy105,500$33.20$3,502,600.00View SEC Filing  
12/8/2016Fredric N EshelmanDirectorBuy621,720$33.77$20,995,484.40View SEC Filing  
9/21/2016Clive MeanwellCEOSell8,623$40.00$344,920.00View SEC Filing  
9/1/2016Clive MeanwellCEOSell1,377$40.00$55,080.00View SEC Filing  
8/24/2016Clive MeanwellCEOSell20,000$40.00$800,000.00View SEC Filing  
7/11/2016Hiroaki ShigetaDirectorSell3,849$38.50$148,186.50View SEC Filing  
6/10/2016Christopher T CoxEVPBuy45,985$37.90$1,742,831.50View SEC Filing  
6/7/2016Christopher T CoxEVPBuy53,340$37.55$2,002,917.00View SEC Filing  
5/24/2016Melvin K SpigelmanDirectorSell15,000$37.00$555,000.00View SEC Filing  
5/16/2016Clive MeanwellCEOSell10,000$35.00$350,000.00View SEC Filing  
5/16/2016William CrouseDirectorSell15,000$35.15$527,250.00View SEC Filing  
5/13/2016Elizabeth H S WyattDirectorSell15,000$34.07$511,050.00View SEC Filing  
5/12/2016Fredric N EshelmanDirectorBuy300,000$33.68$10,104,000.00View SEC Filing  
3/7/2016Armin M KesslerDirectorSell8,100$34.82$282,042.00View SEC Filing  
11/13/2015Robert G. SavageDirectorSell5,000$39.34$196,700.00View SEC Filing  
9/3/2015Glenn SblendorioCFOSell25,000$42.00$1,050,000.00View SEC Filing  
8/31/2015Clive MeanwellCEOSell49,998$39.36$1,967,921.28View SEC Filing  
8/31/2015Glenn SblendorioCFOSell114,495$39.75$4,551,176.25View SEC Filing  
8/31/2015Melvin K. SpigelmanDirectorSell20,000$40.50$810,000.00View SEC Filing  
8/31/2015William Bernard O'connorSVPSell35,451$40.00$1,418,040.00View SEC Filing  
7/1/2015Clive MeanwellCEOSell16,667$28.39$473,176.13View SEC Filing  
6/25/2015Glenn SblendorioCFOSell3,305$32.00$105,760.00View SEC Filing  
6/8/2015Hiroaki ShigetaDirectorSell7,500$28.99$217,425.00View SEC Filing  
5/20/2015Robert G SavageDirectorSell15,000$26.78$401,700.00View SEC Filing  
4/16/2015William Bernard O'connorSVPSell1,281$30.00$38,430.00View SEC Filing  
4/1/2015Clive MeanwellCEOSell16,667$27.58$459,675.86View SEC Filing  
3/30/2015Elizabeth H S WyattDirectorSell20,000$28.08$561,600.00View SEC Filing  
3/23/2015Clive MeanwellCEOSell16,667$30.62$510,343.54View SEC Filing  
3/23/2015Glenn SblendorioCFOSell34,773$30.78$1,070,312.94View SEC Filing  
3/2/2015William Bernard O'connorSVPSell2,988$28.78$85,994.64View SEC Filing  
3/3/2014William Bernard O'connorSVPSell2,968$30.31$89,960.08View SEC Filing  
1/21/2014Paul Michael AntinoriVPSell37,883$38.02$1,440,311.66View SEC Filing  
1/15/2014William Bernard O'connorSVPSell4,427$39.15$173,317.05View SEC Filing  
1/10/2014William Bernard O'connorSVPSell72,384$40.00$2,895,360.00View SEC Filing  
1/7/2014Clive MeanwellCEOSell27,929$38.13$1,064,932.77View SEC Filing  
1/3/2014Clive MeanwellCEOSell57,516$38.16$2,194,810.56View SEC Filing  
12/9/2013William CrouseDirectorSell12,500$38.00$475,000.00View SEC Filing  
12/5/2013Glenn SblendorioCFOSell8,516$38.50$327,866.00View SEC Filing  
12/2/2013Clive MeanwellCEOSell10,000$36.58$365,800.00View SEC Filing  
11/26/2013Clive MeanwellCEOSell135,000$36.70$4,954,500.00View SEC Filing  
10/23/2013William Bernard O'connorSVPSell6,354$35.00$222,390.00View SEC Filing  
9/13/2013Paul Michael AntinoriVPSell73,500$34.50$2,535,750.00View SEC Filing  
9/3/2013Clive MeanwellCEOSell7,500$31.85$238,875.00View SEC Filing  
8/1/2013Clive MeanwellCEOSell7,500$31.26$234,450.00View SEC Filing  
7/8/2013Paul Michael AntinoriVPSell36,000$33.00$1,188,000.00View SEC Filing  
7/1/2013Clive MeanwellCEOSell7,500$31.25$234,375.00View SEC Filing  
6/11/2013Paul Michael AntinoriVPSell109,973$33.29$3,661,001.17View SEC Filing  
5/29/2013Armin M KesslerDirectorSell8,750$33.05$289,187.50View SEC Filing  
5/10/2013Glenn SblendorioCFOSell2,709$37.00$100,233.00View SEC Filing  
5/9/2013Paul Michael AntinoriVPSell35,000$34.90$1,221,500.00View SEC Filing  
5/9/2013William Bernard O'connorSVPSell29,654$35.00$1,037,890.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for The Medicines Company (NASDAQ:MDCO)
Latest Headlines for The Medicines Company (NASDAQ:MDCO)
DateHeadline logoThe Medicines Company (MDCO) PT Raised to $45.00 - July 26 at 5:38 PM logoZacks: Analysts Anticipate The Medicines Company (NASDAQ:MDCO) Will Post Quarterly Sales of $30.51 Million - July 26 at 10:40 AM logoLate-stage study of The Medicines Co's antibiotic combo Vabomere stopped early; U.S. approval likely this quarter; shares ahead 5% premarket - July 26 at 4:48 AM logoThe Medicines Company announces TANGO-2 trial of meropenem-vaborbactam (formerly, Carbavance) stopped early for superior benefit-risk compared to best available therapy for CRE - July 26 at 4:48 AM logoThe Medicines Company announces TANGO-2 trial of meropenem ... - Business Wire (press release) - July 25 at 11:47 PM logoThe Medicines Co. breached its 50 day moving average in a Bullish Manner : MDCO-US : July 24, 2017 - July 24 at 1:27 PM logoSirukumab's Panel And US Decision For Medicines Company - Seeking Alpha - July 22 at 6:21 AM logoReviewing The Medicines (NASDAQ:MDCO) & Depomed (DEPO) - July 21 at 6:10 PM logoCitigroup Inc. Trims The Medicines Company (NASDAQ:MDCO) Target Price to $43.00 - July 17 at 7:15 PM logoReviewing The Medicines Company (MDCO) & Cumberland Pharmaceuticals (CPIX) - July 15 at 7:40 AM logoThe Medicines Company (MDCO) Given Consensus Rating of "Buy" by Analysts - July 11 at 2:10 PM logoAre Medicines Company's Key Drugs Set for Growth in 2017? - July 11 at 1:26 AM logo Analysts Anticipate The Medicines Company (MDCO) Will Post Quarterly Sales of $30.51 Million - June 30 at 1:45 PM logo-$1.18 Earnings Per Share Expected for The Medicines Company (MDCO) This Quarter - June 28 at 4:14 PM logoThe Medicines Company's (MDCO) "Buy" Rating Reiterated at Jefferies Group LLC - June 28 at 11:28 AM logoComparing The Medicines Company (MDCO) & Depomed (DEPO) - June 27 at 8:04 AM logoSanthera's Raxone® Receives First Positive EAMS Scientific Opinion from UK's MHRA in Duchenne Muscular Dystrophy - June 22 at 2:48 AM logoThe Medicines Company (MDCO) Given Consensus Rating of "Buy" by Brokerages - June 16 at 1:08 PM logoWhy Is Alnylam (ALNY) Up 31.2% Since the Last Earnings Report? - June 8 at 10:26 AM logo$30.51 Million in Sales Expected for The Medicines Company (MDCO) This Quarter - June 4 at 8:42 AM logoThe Medicines Company (MDCO) Stock Rating Upgraded by ValuEngine - June 4 at 8:06 AM logoMedicines Co. to cut workforce as it discontinues Ionsys in the U.S. - June 2 at 7:51 PM logoMedicines Co. (MDCO) to Reduce Workforce by 15% - June 2 at 7:51 PM logoThe Medicines Company (MDCO) Expected to Announce Earnings of -$1.17 Per Share - June 2 at 2:36 PM logoThe Medicines Company to Present Data at ASM Microbe 2017 on Infectious Disease Portfolio Including Late-Stage ... - Business Wire (press release) - May 30 at 6:11 PM logoThe Medicines Company to Present Data at ASM Microbe 2017 on Infectious Disease Portfolio Including Late-Stage Investigational Antibiotic Meropenem-Vaborbactam - May 30 at 6:11 PM logoThe Medicines Company (MDCO) Expected to Earn Q3 2017 Earnings of ($1.70) Per Share - May 24 at 8:08 AM logoInvestors Purchase Large Volume of Put Options on The Medicines Company (MDCO) - May 24 at 7:08 AM logoThe Medicines Company (MDCO) Coverage Initiated at CIBC - May 23 at 2:30 PM logoResearch Analysts Offer Predictions for The Medicines Company's Q2 2017 Earnings (MDCO) - May 23 at 7:18 AM logoETFs with exposure to The Medicines Co. : May 22, 2017 - May 22 at 5:50 PM logoThe Medicines Company (MDCO) Given Average Rating of "Buy" by Analysts - May 22 at 12:25 PM logoThe Medicines Company (MDCO) Coverage Initiated at Oppenheimer Holdings Inc. - May 22 at 11:30 AM logoThe Medicines Company (MDCO) Cut to Strong Sell at ValuEngine - May 21 at 8:38 PM logoThis Fund’s Picks Gained 200% In A Year And Why No One Knows About It - May 16 at 6:17 PM logoETFs with exposure to The Medicines Co. : May 11, 2017 - May 11 at 6:58 PM logoThe Medicines Company Gets The Go-Ahead On Novel Cardiovascular Drug - May 9 at 6:11 PM logoThe Medicines Co. :MDCO-US: Earnings Analysis: Q1, 2017 By the Numbers : May 9, 2017 - May 9 at 11:51 AM logoThe Medicines Company (MDCO) Expected to Announce Earnings of -$1.24 Per Share - May 9 at 8:10 AM logoDo Options Traders Know Something About Medicines Company (MDCO) Stock We Don't? - May 8 at 11:59 AM logoDo Options Traders Know Something About Medicines Company (MDCO) Stock We Don't? - May 8 at 11:59 AM logoThe Medicines Company (MDCO) Short Interest Up 3.6% in April - May 7 at 11:22 AM logoThe Medicines Company to Participate in the Bank of America Merrill Lynch 2017 Health Care Conference - Yahoo Finance - May 4 at 6:33 PM logoThe Medicines Company to Participate in the Bank of America ... - Business Wire (press release) - May 4 at 6:33 PM logoThe Medicines Company to Participate in the Bank of America Merrill Lynch 2017 Health Care Conference - May 4 at 11:42 AM logoAlnylam Teams Up With The Medicines Company To Upset PCSK9 Antibody Market - May 1 at 5:29 PM logoThe Medicines Company to Post Q2 2017 Earnings of ($1.40) Per Share, Jefferies Group Forecasts (MDCO) - May 1 at 7:55 AM logoThe Medicines Company (MDCO) Receives News Impact Score of 0.09 - April 29 at 11:33 PM logoMedicines Company (MDCO), Alnylam (ALNY) Announce Agreement with FDA on Phase III Clinical Program for Inclisiran - - April 29 at 12:25 AM logoThe Medicines Company (MDCO) Q1 Loss Wider Than Expected - Yahoo Finance - April 29 at 12:25 AM



The Medicines Company (MDCO) Chart for Thursday, July, 27, 2017

This page was last updated on 7/27/2017 by Staff